Most Recent Articles by Steve Duffy
There are nearly as many migraine patients receiving opioids as there are patients receiving level A abortive medications.
There were positive results from a phase 3 trial (SPARTAN) of the first-in-class drug lasmiditan for the acute treatment of migraine.
The device is applied to the neck and transmits a mild electrical stimulation to the vagus nerve.
Having sickle cell disease did not adversely affect any of the indicators the researchers measured.
The FDA has warned and/or taken action against a number of companies that have made improper claims about the intended use of their products to treat or cure autism.
More Articles by Steve Duffy
Neurology Advisor Articles
- Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence
- Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease
- MRI in Parkinson's Disease: Expanding Usability for Better Diagnostics
- Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability
- The Handoff: Your Week in Neurology News - 9/21/17
- Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease
- Cognitive Decline Related to Site Specific Mid-Life Adiposity
- Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline
- Higher Doses of Pregabalin for Neuropathic Pain: Is it Safe?
- Buccal, Nasal Midazolam Most Cost-Effective for Pediatric Status Epilepticus
- Zika Virus Associated With High Risk for Neurologic Complications in Adults
- Evolocumab Has No Effect on Cognition in Patients Attaining Very Low Levels of LDL Cholesterol
- Acute Oxygen Therapy for Cluster Headahce Not Prohibitively Expensive
- β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD
- Little Evidence to Support Doctor, Patient Electronic Communication Guidelines